GSK-3 Inhibitor IX

Cell permeable: yes

Product competes with ATP.

Reversible: no

Target IC₅₀: 5 nM against GSK-3α/β

Toxicity: Carcinogenic / Teratogenic (D)

A cell-permeable, highly potent, selective, reversible, and ATP-competitive inhibitor of GSK-3α/β (IC₅₀ = 5 nM). Specificity was confirmed using various Cdk′s (IC₅₀ = 83 nM for Cdk5/p25, 300 nM for Cdk2/cyclin A, 320 nM for Cdk1/cyclin B, and 10 µM for Cdk4/cyclin D1), MAP kinases, PKA, PKC isoforms, PKG, CK, and IRTK (IC₅₀ ≥ 10 µM). Inhibition of GSK by BIO has been shown to result in the activation of the Wnt signaling pathway and sustained pluripotency of human and murine embryonic stem cells (ESCs).

Polychronopoulos, P., et al. 2004. J. Med. Chem.47, 935.
Sato, N., et al. 2004. Nat. Med.10, 55.
Meijer, L., et al. 2003. Chem. Biol.10, 1255.

Packaged under inert gas

A 10 mM (500 µg/140 µl) solution of GSK-3 Inhibitor IX (Cat. No. 361550) in DMSO.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany